Current Grant Support

Novartis, “Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of inclisiran” (2021-ongoing), Peterson, Site PI

NIH/NICHD (R21 HD102793 – 01A1), “Biochemical and molecular newborn screening for familial hypercholesterolemia” (2021-2023). Peterson, PI

New England Research Institutes (NERI), “The Dyslipidemia of Obesity Intervention in Teens (DO IT!) Trial” (2019-ongoing). Peterson, Site PI

FH Foundation/Duke University, “The Familial Hypercholesterolemia Foundation CASCADE-FH Registry” (2016-ongoing). Peterson, Site PI

Completed Grant Support

Wisconsin Partnership Program (WPP), “Improved Diagnosis of Pediatric Familial Hypercholesterolemia through the Wisconsin Pediatric Lipid Consortium (WPLC)” (2017-2019), Peterson, PI